Results from a deep learning study demonstrated high accuracy in classifying FGFR3::TACC3 fusion-positive non-small cell lung cancer using hematoxylin and eosin-stained whole-slide images, suggesting that artificial intelligence may identify...
Results from a deep learning study demonstrated high accuracy in classifying FGFR3::TACC3 fusion-positive non-small cell lung cancer using hematoxylin and eosin-stained whole-slide images, suggesting that artificial intelligence may identify...
Results from a health-related quality-of-life analysis of the phase 3 MANEUVER trial demonstrated sustained improvements in patient-reported health status with pimicotinib in patients with tenosynovial giant cell tumor, with benefits...
Results from a health-related quality-of-life analysis of the phase 3 MANEUVER trial demonstrated sustained improvements in patient-reported health status with pimicotinib in patients with tenosynovial giant cell tumor, with benefits...
Updated 2-year results from the phase 3 MANEUVER trial demonstrated sustained improvements in pain, stiffness, range of motion, and physical function with pimicotinib in patients with tenosynovial giant cell tumor, alongside durable tumor...
Updated 2-year results from the phase 3 MANEUVER trial demonstrated sustained improvements in pain, stiffness, range of motion, and physical function with pimicotinib in patients with tenosynovial giant cell tumor, alongside durable tumor...
Results from a clinical validation study demonstrated that cell-free DNA methylation-based fusion epigenotyping detected non-EML4-ALK fusions in non-small cell lung cancer with high sensitivity and specificity, supporting its potential to...
Results from a clinical validation study demonstrated that cell-free DNA methylation-based fusion epigenotyping detected non-EML4-ALK fusions in non-small cell lung cancer with high sensitivity and specificity, supporting its potential to...
Updated results from the phase 2 FIREFLY-1 trial demonstrated prolonged treatment-free intervals with tovorafenib in relapsed or refractory BRAF-altered pediatric low-grade glioma, with most patients entering observation remaining off therapy...
Updated results from the phase 2 FIREFLY-1 trial demonstrated prolonged treatment-free intervals with tovorafenib in relapsed or refractory BRAF-altered pediatric low-grade glioma, with most patients entering observation remaining off therapy...
Results from a biomarker analysis of the phase 3 INDIGO trial demonstrated improved progression-free survival with vorasidenib across baseline IDH variant allele frequency subgroups in patients with grade 2 IDH-mutant glioma, supporting...
Results from a biomarker analysis of the phase 3 INDIGO trial demonstrated improved progression-free survival with vorasidenib across baseline IDH variant allele frequency subgroups in patients with grade 2 IDH-mutant glioma, supporting...
Updated American Cancer Society prostate cancer screening guidelines recommend regular PSA-based testing for average-risk patients and earlier, more frequent screening for higher-risk patients, emphasizing early detection, confirmatory...
Updated American Cancer Society prostate cancer screening guidelines recommend regular PSA-based testing for average-risk patients and earlier, more frequent screening for higher-risk patients, emphasizing early detection, confirmatory...
Based on results from the evERA Breast Cancer trial, the FDA has approved giredestrant plus everolimus for previously treated patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer, demonstrating improved...
Based on results from the evERA Breast Cancer trial, the FDA has approved giredestrant plus everolimus for previously treated patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer, demonstrating improved...
Based on results from the phase 3 VOLGA trial, the FDA has approved neoadjuvant durvalumab plus enfortumab vedotin followed by adjuvant durvalumab for patients with muscle-invasive bladder cancer who are ineligible for or have refused...
Based on results from the phase 3 VOLGA trial, the FDA has approved neoadjuvant durvalumab plus enfortumab vedotin followed by adjuvant durvalumab for patients with muscle-invasive bladder cancer who are ineligible for or have refused...
The FDA approved pimicotinib, an oral kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor when surgery may cause worsening functional limitations or severe morbidity, based on the results from the phase 3 MANEUVER...
The FDA approved pimicotinib, an oral kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor when surgery may cause worsening functional limitations or severe morbidity, based on the results from the phase 3 MANEUVER...